{
  "meta": {
    "title": "49_Anti-Diabetic_Drugs_-_Oral",
    "url": "https://brainandscalpel.vercel.app/49-anti-diabetic-drugs-oral-c1ca2dd0.html",
    "scrapedAt": "2025-11-30T12:34:31.477Z"
  },
  "questions": [
    {
      "text": "Which of the following does not cause insulin release?",
      "choices": [
        {
          "id": 1,
          "text": "Rosiglitazone"
        },
        {
          "id": 2,
          "text": "Nateglinide"
        },
        {
          "id": 3,
          "text": "Glimepiride"
        },
        {
          "id": 4,
          "text": "Tolbutamide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Rosiglitazone</strong> does not increase insulin release from the beta cells of the pancreas.</p>\n<p>Rosiglitazone is a <strong>thiazolidinedione</strong> that acts by<strong> activating PPAR-gamma</strong>&nbsp;(nuclear receptor) which induces several genes involved in lipid and glucose metabolism and<strong>&nbsp;</strong>thereby<strong>, decreases insulin resistance.</strong></p>\n<p>Nateglinide (a <strong>meglitinide</strong>) and glimepiride, tolbutamide (both <strong>sulfonylureas</strong>) are <strong>insulin secretagogues</strong> that act by inhibiting the ATP-sensitive K+ channels of the beta cells of the pancreas to cause insulin release.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1868",
      "difficulty": "easy"
    },
    {
      "text": "Insulin release due to the closure of K+ channels is seen with?",
      "choices": [
        {
          "id": 1,
          "text": "Repaglinide"
        },
        {
          "id": 2,
          "text": "Metformin"
        },
        {
          "id": 3,
          "text": "Exenatide"
        },
        {
          "id": 4,
          "text": "Sitagliptin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Repaglinide </strong>acts by<strong> increasing insulin secretion</strong> by<strong> blockage of ATP-sensitive K+ channels </strong>of the beta cells of the pancreas.</p>\n<p>When ATP-sensitive K+ channels are blocked, it will lead to depolarization of beta cells and the release of insulin.</p>\n<p><strong>Sulfonylureas </strong>also act by this <strong>similar mechanism.</strong></p>\n<p>Option B - Metformin is an insulin sensitizer and also inhibits gluconeogenesis and increases hepatic uptake of glucose.</p>\n<p>Option C - Exenatide is a GLP-1 analog.</p>\n<p>Option D - Sitagliptin is a DPP-4 inhibitor.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/263f29c8c67841b594bb001f8af7a1b8x808x550.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1889",
      "difficulty": "medium"
    },
    {
      "text": "A diabetic patient being treated with an oral hypoglycemic agent develops dilutional hyponatremia. Which one of the following could be responsible for the effect?",
      "choices": [
        {
          "id": 1,
          "text": "Tolbutamide"
        },
        {
          "id": 2,
          "text": "Chlorpropamide"
        },
        {
          "id": 3,
          "text": "Glyburide"
        },
        {
          "id": 4,
          "text": "Glimepiride"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Chlorpropamide </strong>use is <strong>associated</strong> with<strong> dilutional hyponatremia.</strong></p>\n<p>It is a first generation sulfonylurea and can lead to<strong> SIADH.</strong></p>\n<p>Along with alcohol use,it can also lead to <strong>disulfiram-like reaction.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3582",
      "difficulty": "medium"
    },
    {
      "text": "A 62-year-old woman presents with complaints of fatigue. She is a known case of type 2 diabetes mellitus on treatment. On examination, there is pallor and knuckle pigmentation. Which of the following drugs could have caused her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Gliclazide"
        },
        {
          "id": 2,
          "text": "Acarbose"
        },
        {
          "id": 3,
          "text": "Metformin"
        },
        {
          "id": 4,
          "text": "Rosiglitazone"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Metformin</strong> can cause <strong>vitamin B12 deficiency</strong> which manifests as <strong>megaloblastic anemia</strong>&nbsp;(pallor, fatigue) with <strong>knuckle pigmentation</strong>.</p>\n<p>The most common side effect of metformin is <strong>GI intolerance</strong> as nausea, bloating, abdominal cramps and diarrhoea.</p>\n<p>Note: The exact reason why metformin causes vitamin B12 deficiency is not known.&nbsp;</p>\n<p>The proposed mechanisms include:</p>\n<ul>\n<li>Alterations in small bowel motility, which stimulates bacterial overgrowth and consequential vitamin B12 deficiency</li>\n<li>Competitive inhibition or inactivation of vitamin B12 absorption</li>\n<li>Alterations in intrinsic factor (IF) levels and interaction with the cubilin endocytic receptor.</li>\n<li>Inhibition of the calcium-dependent absorption of the vitamin B12-IF complex at the terminal ileum.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1848",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is incorrect regarding metformin?",
      "choices": [
        {
          "id": 1,
          "text": "Causes little or no hypoglycemia in non-diabetic patients"
        },
        {
          "id": 2,
          "text": "Acts by increased insulin secretion"
        },
        {
          "id": 3,
          "text": "Increases peripheral utilization of glucose and decreases absorption of glucose from the intestine"
        },
        {
          "id": 4,
          "text": "Increase intake of calcium may prevent metformin induced B12 malabsorption"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Metformin does <strong>not</strong> act by <strong>increasing insulin secretion.</strong></p>\n<p>It <strong>decreases insulin resistance </strong>and <strong>increases the peripheral utilization of glucose.</strong></p>\n<p>Metformin is a <strong>biguanide</strong> that acts by activation of AMP-dependent protein kinase activation and thereby mediates a series of actions that helps in <strong>reducing hepatic glucose production.</strong></p>\n<p>Option A - Metformin has minimal to nil effect on insulin secretion and as a result, has <strong>minimal or no hypoglycemic effect</strong> in non-diabetic patients.</p>\n<p>Option C - Metformin reduces hepatic gluconeogenesis, increases the insulin-mediated peripheral glucose uptake and also decreases the absorption of glucose from the gut.</p>\n<p>Option D - Increase intake of calcium will decrease the B12 malabsorption because metformin <strong>interferes with Ca<sup>2+</sup> dependent B12 absorption</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1890",
      "difficulty": "easy"
    },
    {
      "text": "What is the central pharmacological action of metformin in type 2 diabetes?",
      "choices": [
        {
          "id": 1,
          "text": "Reduction in glucose absorption"
        },
        {
          "id": 2,
          "text": "Reduction in insulin resistance"
        },
        {
          "id": 3,
          "text": "Reduction in hepatic glucose production"
        },
        {
          "id": 4,
          "text": "Reduction in effects of glucagon"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The central pharmacological action of metformin is to <strong>reduce hepatic glucose production by inhibiting gluconeogenesis</strong>. Metformin effect is mainly mediated through activation of AMPK and altering the energy dynamics at mitochondrial respiration.&nbsp;</p>\n<p>Option A - The <strong>reduction in glucose absorption</strong> can also occur but the contribution to the antihyperglycemic action is not significant</p>\n<p>Option B - Metformin<strong> increases peripheral glucose utilization</strong> by both insulin-dependent (reducing insulin resistance) and independent ways. But the current evidence does not support the reduction in insulin resistance as the primary mechanism of metformin's action.</p>\n<p>Option D - Recent evidence shows <strong>blunting of glucagon effects</strong> as one of the mechanisms of metformin's action</p>\n<p>Note: All are mechanisms of metformin, however, the key action is Option C and it is the most appropriate answer.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3593",
      "difficulty": "medium"
    },
    {
      "text": "A 58-year-old woman with chronic kidney disease with recently diagnosed Type 2 DM was started on metformin therapy. Her repeat eGFR was 40/min/1.73 m2. Which of the following is not true regarding the further management of this lady?",
      "choices": [
        {
          "id": 1,
          "text": "Metformin dose has to be decreased."
        },
        {
          "id": 2,
          "text": "Metformin should be discontinued and replaced with insulin."
        },
        {
          "id": 3,
          "text": "eGFR should be measured at least annually in her."
        },
        {
          "id": 4,
          "text": "eGFR is preferred over serum creatinine concentration to assess renal function for metformin therapy."
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>According to current guidelines (KDIGO 2020),&nbsp;metformin should be <strong>discontinued</strong> only in patients with <strong>eGFR less than 30</strong> ml/min/1.73 m<sup>2</sup>&nbsp;or kidney failure. Metformin dose should be <strong>reduced</strong> when the <strong>eGFR is less than 45</strong> ml/min/1.73 m<sup>2</sup>.</p>\n<p>Metformin is<strong> excreted by the kidneys</strong>, and accumulation with reduced kidney function may increase the <strong>risk</strong> <strong>of lactic acidosis </strong>(due to inhibition of hepatic gluconeogenesis).&nbsp;It is contraindicated below <strong>eGFR&lt;30.</strong>&nbsp;</p>\n<p><strong>eGFR</strong> is obtained at baseline and <strong>at least annually</strong> in all patients taking metformin. It is recommended that the eligibility of CKD patients for metformin administration be changed from one based on a single laboratory parameter (blood creatinine concentration) to one that provides a <strong>better estimate of kidney function</strong> in patients with <strong>kidney disease</strong> i.e., glomerular filtration rate estimating equation (eGFR).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3584",
      "difficulty": "medium"
    },
    {
      "text": "A 13-year-old boy is diagnosed with type 2 diabetes mellitus. Which of the following drugs can be prescribed?",
      "choices": [
        {
          "id": 1,
          "text": "Glimepiride"
        },
        {
          "id": 2,
          "text": "Metformin"
        },
        {
          "id": 3,
          "text": "Sitagliptin"
        },
        {
          "id": 4,
          "text": "Pioglitazone"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Metformin </strong>can be prescribed as it is<strong>&nbsp;FDA approved </strong>for medical treatment of<strong> type 2 diabetes</strong> <strong>in pediatric</strong> <strong>population</strong> as young as 10 years of age.</p>\n<p>It is available as a liquid oral formulation (100mg/ml) for pediatric use.&nbsp;</p><p>The U.S.FDA has recently approved<strong>&nbsp;Liraglutide injection</strong> for the treatment of type 2 diabetes in the <strong>pediatric age</strong> group of 10 years and above. It is the first non-insulin drug approved for the treatment of type 2 diabetes in pediatric patients since metformin, which was approved for pediatric use in 2000.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3588",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is incorrect regarding pioglitazone?",
      "choices": [
        {
          "id": 1,
          "text": "Metabolised in the liver by CYP3A4"
        },
        {
          "id": 2,
          "text": "Selective agonist for the nuclear peroxisome proliferator activated receptor"
        },
        {
          "id": 3,
          "text": "It can modulate the transcription of genes for carbohydrate and fat metabolism in the absence of insulin"
        },
        {
          "id": 4,
          "text": "It should be avoided in any patient with cardiovascular disease"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Pioglitazone need <strong>not</strong> be avoided in <strong>all</strong> patients with cardiovascular disease.</p>\n<p><strong>Pioglitazone</strong> is known to cause <strong>fluid retention</strong> and edema and is therefore <strong>avoided in patients who have heart failure</strong>. It is not avoided in all cardiovascular diseases.&nbsp;</p>\n<p>Option A - Pioglitazone is metabolized by <strong>CYP3A4 and CYP2C8.</strong>&nbsp;</p>\n<p>Option B - Pioglitazone is a <strong>selective agonist of nuclear peroxisome proliferator-activated receptor</strong> (PPAR).&nbsp; It modulates the expression of genes involved in lipid and glucose metabolism, insulin signal transduction and adipocyte differentiation. These effects increase the sensitivity of the tissues to insulin.</p>\n<p>Option C - Pioglitazone does not increase insulin levels in the body. It <strong>sensitizes the tissues to the action of insulin</strong>. Hence, insulin is needed for the action of pioglitazone. However, it does not need insulin to modulate the expression of genes.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1855",
      "difficulty": "hard"
    },
    {
      "text": "A 55-year-old diabetic man on treatment presents with complaints of difficulty reading. Fundoscopy shows the following findings. Which antidiabetic drug class is likely to cause this?",
      "choices": [
        {
          "id": 1,
          "text": "Thiazolidinediones"
        },
        {
          "id": 2,
          "text": "DPP-4 inhibtors"
        },
        {
          "id": 3,
          "text": "SGLT-2 inhibitors"
        },
        {
          "id": 4,
          "text": "Sulfonylureas"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The image shows <strong>diabetic macular edema</strong>, with hard exudates surrounding the blood vessels.&nbsp;It is a rare adverse effect seen with <strong>thiazolidinediones,</strong> and it resolves when the drug is discontinued.&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/20bee22a7c7d4df1b8fc065782163abd.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3611",
      "difficulty": "medium"
    },
    {
      "text": "An elderly man was diagnosed with hypertension 2 years ago and has been on losartan. During a routine health checkup, his HbA1c was found to be 7.3%. Which of the following is a better alternative to losartan for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Irbesartan"
        },
        {
          "id": 2,
          "text": "Telmisartan"
        },
        {
          "id": 3,
          "text": "Candesartan"
        },
        {
          "id": 4,
          "text": "Olmesartan"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This patient has hypertension and <strong>diabetes mellitus</strong> (HbA1c &gt;6.5% is diagnostic for diabetes). <strong>Telmisartan</strong> would be a better alternative to losartan in patients with both <strong>hypertension and diabetes</strong>, due to its <strong>additional&nbsp;PPAR gamma agonist</strong> action.</p>\n<p>PPAR gamma agonists act by inducing several insulins sensitizing genes and thereby <strong>reducing the overall insulin resistance</strong>.&nbsp;</p>\n<p>While other angiotensin receptor blockers have been found to have PPAR gamma action, telmisartan has the highest and has been extensively studied in diabetes.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1875",
      "difficulty": "easy"
    },
    {
      "text": "A 60-year-old woman with a known history of hypertension and dyslipidemia was admitted for evaluation of recurrent TIA. On workup, she was diagnosed with diabetes mellitus. Which of the following drugs should be avoided in the management of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Pioglitazone"
        },
        {
          "id": 2,
          "text": "Rosiglitazone"
        },
        {
          "id": 3,
          "text": "Metformin"
        },
        {
          "id": 4,
          "text": "Troglitazone"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Rosiglitazone</strong> should be avoided as it <strong>increases the risk of cardiovascular events</strong> like myocardial infarction and stroke.</p>\n<p>It remains banned in Europe, India, and other countries. It has not been withdrawn in the US and is marketed with a black box warning of increased risk of <strong>myocardial infarction and stroke</strong>.&nbsp;</p>\n<p>Option A: Several studies have shown relative cardiovascular safety of pioglitazone over rosiglitazone.</p>\n<p>Option C: Metformin use is associated with decreased risk of microvascular complications in diabetes.&nbsp;</p>\n<p>Option D: Troglitazone was withdrawn due to increased hepatotoxicity.&nbsp;&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3587",
      "difficulty": "medium"
    },
    {
      "text": "A professional boxer is diagnosed with diabetes mellitus. He is concerned about weight changes as a side effect of anti-diabetic drugs and explains that he has to maintain his current weight category. Which of the following will you prescribe?",
      "choices": [
        {
          "id": 1,
          "text": "Pioglitazone"
        },
        {
          "id": 2,
          "text": "Saxagliptin"
        },
        {
          "id": 3,
          "text": "Liraglutide"
        },
        {
          "id": 4,
          "text": "Gliclazide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Saxagliptin</strong>, a <strong>DPP-4 inhibitor</strong>, can be prescribed for this patient as it has a <strong>weight-neutral</strong>&nbsp;effect.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>EFFECT</strong></td>\n<td><strong>DRUGS</strong></td>\n</tr>\n<tr>\n<td>Weight gain</td>\n<td>Sulfonylureas, Insulin,&nbsp;<span class=\"_Tgc _s8w\">Thiazolidinediones</span></td>\n</tr>\n<tr>\n<td>Weight loss</td>\n<td>GLP-1 analogues, Pramlintide, SGLT-2 inhibitors, Metformin*</td>\n</tr>\n<tr>\n<td><strong>Weight neutral</strong></td>\n<td>Alpha-glucosidase inhibitors, <strong>DPP-4 inhibitors</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note: *Metformin classification is a bit difficult. It can cause mild weight loss in some patients but few authorities do consider metformin as weight neutral.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1859",
      "difficulty": "medium"
    },
    {
      "text": "In a middle-aged diabetic patient with chronic kidney disease stage 5, which of the following drugs can be given safely without altering the dose?",
      "choices": [
        {
          "id": 1,
          "text": "Vildagliptin"
        },
        {
          "id": 2,
          "text": "Linagliptin"
        },
        {
          "id": 3,
          "text": "Saxagliptin"
        },
        {
          "id": 4,
          "text": "Sitagliptin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Linagliptin</strong> can be given safely without altering the dose for this patient.</p>\n<p>Linagliptin is a <strong>dipeptidyl-peptidase-4 (DPP-4) inhibitor</strong>&nbsp;and is <strong>eliminated</strong> by the<strong>&nbsp;hepatobiliary route.&nbsp;</strong>Hence no dosage adjustment is needed in renal failure.</p>\n<p>It is used in type 2 diabetes as monotherapy or as combination therapy with other drugs when metformin is not tolerated or contraindicated.</p>\n<p><strong>Other DPP-4 inhibitors</strong>&nbsp;like sitagliptin, vildagliptin, saxagliptin, alogliptin show <strong>renal elimination</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9510",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not true about dapagliflozin?",
      "choices": [
        {
          "id": 1,
          "text": "It is indicated in heart failure"
        },
        {
          "id": 2,
          "text": "It causes weight gain"
        },
        {
          "id": 3,
          "text": "It is effective orally"
        },
        {
          "id": 4,
          "text": "It will increase the risk of fractures"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Dapagliflozin </strong>does not cause weight gain. It results in <strong>weight loss.</strong></p>\n<p>It acts by <strong>inhibiting </strong>the<strong> SGLT2 </strong>(sodium glucose-2) transporter, which is present on the proximal segment of the renal tubule and responsible for the reabsorption of 80-90% of filtered glucose. It&nbsp;inhibits glucose reabsorption resulting in <strong>glycosuria</strong> and a decrease in blood glucose level. It is effective<strong> orally.</strong></p>\n<p>The common adverse effects include urinary tract infections and genital mycotic infections due to the high glucose content of the urine and also<strong>&nbsp;the high risk of fractures</strong>.</p>\n<p>Other SGLT2 inhibitors include empagliflozin, canagliflozin, and ertugliflozin.</p>\n<p>Note: Empagliflozin has been found to decrease the risk of mortality from cardiovascular causes in diabetic patients. <strong>Dapagliflozin</strong> has been recently approved by the FDA for the treatment of heart failure with reduced ejection fraction(<strong>HFrEF</strong>) in both <strong>diabetic</strong> and <strong>non-diabetic patients</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1870",
      "difficulty": "medium"
    },
    {
      "text": "A patient with diabetes mellitus came to the OPD with a history suggestive of recurrent episodes of hypoglycemia. She was recently put on combination therapy. Her symptoms are least likely to be caused by which of the following drugs?",
      "choices": [
        {
          "id": 1,
          "text": "Acarbose"
        },
        {
          "id": 2,
          "text": "Insulin"
        },
        {
          "id": 3,
          "text": "Gliclazide"
        },
        {
          "id": 4,
          "text": "Repaglinide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Acarbose</strong> is&nbsp;least likely to cause hypoglycemia among the given options.</p>\n<p>It&nbsp;is an alpha-glucosidase inhibitor. It inhibits the intestinal degradation and absorption of starch and disaccharides&nbsp;and thereby lowers the postprandial rise in glucose levels.</p>\n<p>It has<strong> no role in stimulating insulin secretion</strong> and is therefore,&nbsp;<strong>least likely to cause hypoglycemia</strong> during monotherapy.&nbsp;</p>\n<p>Insulin and insulin secretagogues like sulfonylureas (gliclazide) and meglitinides (repaglinide) can result in hypoglycemia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1853",
      "difficulty": "medium"
    },
    {
      "text": "While at a bakery, a man complains of giddiness and palpitations. As the only doctor there, you're asked for help. The man says he had just taken his diabetic medications and shows a prescription listing insulin and acarbose. What would you give for immediate management?",
      "choices": [
        {
          "id": 1,
          "text": "Honey"
        },
        {
          "id": 2,
          "text": "Bread"
        },
        {
          "id": 3,
          "text": "Sugar"
        },
        {
          "id": 4,
          "text": "Cake"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Giddiness and palpitations after taking insulin and acarbose are suggestive of <strong>hypoglycemia</strong>.&nbsp;<strong>Honey</strong>&nbsp;is the most suitable agent among the given options for the&nbsp;<strong>management of hypoglycemia</strong> in a patient who is on <strong>acarbose</strong> therapy.</p>\n<p>Acarbose is an <strong>alpha-glucosidase inhibitor.</strong> It inhibits the intestinal degradation of starch and disaccharides&nbsp;into glucose. Honey contains<strong> monosaccharides </strong>(fructose and glucose) that do not need to be broken down and are <strong>directly absorbed</strong> and would be beneficial in hypoglycemia caused by alpha-glucosidase inhibitors.&nbsp;However, glucose or dextrose tablets is recommended when available.</p>\n<p>While alpha-glucosidase inhibitors themselves do not cause hypoglycemia, the risk of hypoglycemia is increased when they are taken along with insulin or insulin secretagogues.</p>\n<p>Disaccharides and complex carbohydrates will not be completely broken down and absorbed in a patient who is on alpha-glucosidase inhibitors.</p>\n<p>Option B -&nbsp;Bread predominantly contains <strong>complex carbohydrates</strong> like <strong>starch</strong></p>\n<p>Option C - Sugar contains <strong>sucrose</strong>, a <strong>disaccharide</strong></p>\n<p>Option D - Cake contains sugar (disaccharide) and other complex carbohydrates</p><p>The U.S. FDA approved Baqsimi nasal powder (3 mg), the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered through a single-use dispenser (without an injection).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1866",
      "difficulty": "medium"
    },
    {
      "text": "A 52-year-old diabetic patient presented to the ED with complaints of chest pain on exertion. Laboratory tests showed dyslipidemia and features of metabolic syndrome. Which of the following drugs was recently approved for this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Aleglitazar"
        },
        {
          "id": 2,
          "text": "Saroglitazar"
        },
        {
          "id": 3,
          "text": "Muraglitazar"
        },
        {
          "id": 4,
          "text": "Rosiglitazone"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Saroglitazar </strong>is a <strong>dual PPAR alpha/gamma agonist</strong>&nbsp;and is approved for <strong>diabetic dyslipidemia</strong> only in India.</p>\n<p><strong>Peroxisome proliferator-activated receptors</strong> (PPARs) are a superfamily of nuclear receptors involved&nbsp;in the regulation of energy homeostasis and metabolic function.&nbsp;It has three subtypes:</p>\n<ul>\n<li>PPAR&alpha; - reduces triglyceride level&nbsp;</li>\n<li>PPAR&gamma; - causes insulin sensitization&nbsp;</li>\n<li>PPAR&delta; - enhances fatty acids metabolism</li>\n</ul>\n<p>Of the three PPAR isoforms, synthetic pharmaceutical ligands that activate <strong>PPARalpha</strong> (the antidyslipidemic <strong>fibrates)</strong> and <strong>PPARgamma</strong> (the antidiabetic <strong>thiazolidinediones)</strong> have been studied extensively. Recently developed dual PPARalpha/gamma agonists combine the therapeutic effects of these drugs to be used in <strong>type 2 diabetes with dyslipidemia.&nbsp;</strong></p>\n<p>Options A and C - Aleglitazar and muraglitazar are also dual PPAR alpha/gamma agonists but their development was halted due to increased risk of cardiovascular mortality.</p>\n<p>Option D - Rosiglitazone is a PPAR gamma agonist indicated in type 2 diabetes mellitus. It has been withdrawn from many countries including India due to increased cardiovascular mortality.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3605",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is approved as an adjunctive treatment for type 2 diabetes mellitus?",
      "choices": [
        {
          "id": 1,
          "text": "Bromocriptine"
        },
        {
          "id": 2,
          "text": "Phenytoin"
        },
        {
          "id": 3,
          "text": "Ropinirole"
        },
        {
          "id": 4,
          "text": "Metoclopromide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Bromocriptine </strong>is a <strong>dopamine agonist </strong>that has been approved as an adjunctive treatment for <strong>diabetes mellitus.</strong></p>\n<p>The exact mechanism is unknown but may involve alteration in circadian (hypothalamic) control of blood glucose levels. A fast-release, low-dose formulation of bromocriptine is approved for type 2 diabetes that has to be<strong> administered within 3 hours of awakening.</strong></p>\n<p>Option B - Phenytoin is a Na<sup>+</sup> channel blocker and is an antiepileptic drug</p>\n<p>Option C - Ropinirole is an antiparkinsonian drug that is a dopamine agonist and is also approved for treatment of restless leg syndrome</p>\n<p>Option D - Metoclopramide is a 5HT<sub>4</sub> agonist and D<sub>2</sub> blocker and used as an antiemetic agent</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1876",
      "difficulty": "easy"
    },
    {
      "text": "A 54-year-old woman comes to the diabetic clinic for follow up. Her lipid profile shows high LDL cholesterol. Which bile acid sequestrant would you prescribe for her?",
      "choices": [
        {
          "id": 1,
          "text": "Colesevelam"
        },
        {
          "id": 2,
          "text": "Colestipol"
        },
        {
          "id": 3,
          "text": "Cholestyramine"
        },
        {
          "id": 4,
          "text": "Ezetimibe"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Colesevelam</strong>&nbsp;can be prescribed for her as it is the only <strong>bile acid sequestrant </strong>that is specifically <strong>approved</strong> for<strong>&nbsp;</strong>the treatment of type 2<strong> diabetes mellitus.&nbsp;</strong></p>\n<p>It is used to <strong>reduce LDL cholesterol&nbsp;</strong>and<strong> improve glycemic control</strong> in diabetics.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3599",
      "difficulty": "medium"
    }
  ]
}